By week 17 and beyond, most patients report substantially reduced nausea and diarrhea compared to the escalation phase
The addition of GIP activation amplifies effects beyond what either receptor could achieve alone
A separate 2025 trial in NEJM Evidence (Shah et al.) in adults with T1D and obesity on AID found that around one in three semaglutide-treated participants met a combined goal of improved time in range, low hypoglycemia, and at least 5% weight loss
Being overweight and obese contributes to numerous health conditions, including cardiovascular disease, diabetes, sleep and musculoskeletal disorders, stroke, hormonal issues, certain cancers and a decreased lifespan
Proper dose titration (starting low and increasing gradually) significantly reduces nausea with both compounds
One of the most common questions is whether you should stop suddenly or taper gradually